Literature DB >> 12690043

Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies.

Heinz Wiendl1, Meike Mitsdoerffer, Dagmar Schneider, Arthur Melms, Hanns Lochmuller, Reinhard Hohlfeld, Michael Weller.   

Abstract

Inducible co-stimulator ligand (ICOSL), a member of the B7 family of co-stimulatory molecules related to B7.1/2, regulates CD4 as well as CD8 T-cell responses via interaction with its receptor ICOS on activated T cells. Here we examined the expression and the functional relevance of ICOSL in human muscle cells in vivo and in vitro. We investigated 25 muscle biopsy specimens from patients with polymyositis, dermatomyositis, inclusion body myositis, Duchenne muscular dystrophy and non-myopathic controls for ICOSL expression by immunohistochemistry. Normal muscle fibres constitutively express low levels of ICOSL. However, ICOSL expression is markedly increased in muscle fibres in inflammatory myopathies. Cell surface staining was most prominent in the contact areas between muscle fibres and inflammatory cells, which in turn show expression of ICOS as a marker of T-cell activation. Muscle endothelial cells show constitutive expression of ICOSL under normal and pathological conditions. We also detected mRNA and cell surface protein expression of ICOSL on myoblasts cultured from control subjects and patients as well as in TE671 muscle rhabdomyosarcoma cells. ICOSL expression was upregulated by tumour necrosis factor-alpha (TNF-alpha), whereas interferon-gamma (IFN-gamma) had no such effect. Co-culture experiments of major histocompatibility complex (MHC) class II-positive myoblasts with CD4 T cells together with superantigen demonstrated that the expression of muscle-related ICOSL has functional consequences: the production of Th1 (IFN-gamma) and Th2 cytokines [interleukin (IL)-4 and IL-10] by CD4 T cells was markedly reduced in the presence of a neutralizing anti-ICOSL monoclonal antibody (mAb HIL-131), thus showing the importance of ICOSL co-stimulation for T-cell activation. Taken together, our results demonstrate that human muscle cells express ICOSL, a functional co-stimulatory molecule distinct from B7.1 and B7.2. ICOSL-ICOS interactions may play an important role in inflammatory myopathies, providing further evidence for the antigen-presenting capacity of muscle cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12690043     DOI: 10.1093/brain/awg114

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  19 in total

1.  Human vascular smooth muscle cells lack essential costimulatory molecules to activate allogeneic memory T cells.

Authors:  Pei Zhang; Thomas D Manes; Jordan S Pober; George Tellides
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-06-10       Impact factor: 8.311

2.  Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells.

Authors:  Natalia Martin-Orozco; Yufeng Li; Yijun Wang; Shijuan Liu; Patrick Hwu; Yong-Jun Liu; Chen Dong; Laszlo Radvanyi
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

3.  Costimulation and pancreatic autoimmunity: the PD-1/PD-L conundrum.

Authors:  Deepak Yadav; Nora Sarvetnick
Journal:  Rev Diabet Stud       Date:  2006-05-10

Review 4.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

5.  Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.

Authors:  Sareetha Kailayangiri; Bianca Altvater; Christian Spurny; Silke Jamitzky; Sonja Schelhaas; Andreas H Jacobs; Constanze Wiek; Katharina Roellecke; Helmut Hanenberg; Wolfgang Hartmann; Heinz Wiendl; Susann Pankratz; Jutta Meltzer; Nicole Farwick; Lea Greune; Maike Fluegge; Claudia Rossig
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

Review 6.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

7.  Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin.

Authors:  John H Boyd; Maziar Divangahi; Linda Yahiaoui; Dusanka Gvozdic; Salman Qureshi; Basil J Petrof
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

8.  Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.

Authors:  Katja Simon-Keller; Annette Paschen; Andreas A Hombach; Philipp Ströbel; Jean-Michel Coindre; Stefan B Eichmüller; Angela Vincent; Stefan Gattenlöhner; Florian Hoppe; Ivo Leuschner; Sabine Stegmaier; Ewa Koscielniak; Martin Leverkus; Dario C Altieri; Hinrich Abken; Alexander Marx
Journal:  Am J Pathol       Date:  2013-04-02       Impact factor: 4.307

Review 9.  Inflammation induced loss of skeletal muscle.

Authors:  Priya Londhe; Denis C Guttridge
Journal:  Bone       Date:  2015-11       Impact factor: 4.398

10.  Calcium/Calmodulin-Dependent Protein Kinase IV (CaMKIV) Mediates Acute Skeletal Muscle Inflammatory Response.

Authors:  DanDan Shi; RuiCai Gu; YaFeng Song; MaoChao Ding; Tao Huang; MengXia Guo; JiangWei Xiao; WenHua Huang; Hua Liao
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.